ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and ...

The National Institute for Health and Care Excellence (NICE) has recommended exagamglogene autotemcel (Casgevy, Vertex) – commonly known as 'exa-cel' – to treat transfusion-dependent beta thalassaemia ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending a CRISPR gene editing-based treatment for severe sickle cell disease (SCD). The regulator said ...

(ORLANDO, Dec. 6, 2025) Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell ...

England’s National Institute for Health and Care Excellence has yet to sign off on Casgevy's use in sickle cell disease. (Ismail Rajo/Getty Images) On the rocky road to ensuring access to gene therapy ...

Preliminary results from two trials of the gene therapy exagamglogene autotemcel (exa-cel) suggest the therapy offers an effective cure for beta-thalassemia and sickle cell disease in children younger ...

Transfusion-dependent beta thalassemia requires consistent red blood cell transfusions to maintain adequate hemoglobin levels. Exa-cel, a CRISPR-based gene therapy, removes a patient's own ...

Some with severe sickle cell disease in England will now be able to access landmark CRISPR gene editing therapy, according to ...

ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

We are getting closer to a world where the debilitating pain and complications of sickle cell disease are a thing of the past. For the 17,500 people in the UK living with this genetic condition, this ...